Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

International Journal of Clinical Oncology

Volumn 10, Issue 6, 2005, Pages 405-410

  Uemura, Hiroji ^a   Hasumi, Hisashi ^a   Kawahara, Takashi ^a   Sugiura, Shinpei ^a   Miyoshi, Yasuhide ^a   Nakaigawa, Noboru ^a   Teranishi, Jun Ichi ^b   Noguchi, Kazumi ^b   Ishiguro, Hitoshi ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Angiotensin II receptor blocker; Hormone refractory prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANDROGEN; CANDESARTAN; CANDESARTAN HEXETIL; DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER HORMONE THERAPY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSTASIS; HUMAN; HUMAN TISSUE; HYPOTENSION; LIVER TOXICITY; MALE; NEPHROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTINEOPLASTIC AGENTS, HORMONAL; BENZIMIDAZOLES; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; TETRAZOLES;

EID: 29244485406     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-005-0520-y     Document Type: Article

References (27)

1. A Jemal A Thomas T Murray 2002 Cancer Statistics CA Cancer J Clin 52 23 47
2. The Research Group for Population-Based Cancer Registration in Japan 2004 Cancer incidence in Japan K Tajima T Kuroishi A Oshima Cancer mortality and morbidity statistics. Monograph on cancer research, No. 51 Japan Scientific Societies Press Karger, Tokyo 95 99
3. DP Petrylak CM Tangen MH Hussain 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520
4. G Liu K Oettel G Ripple 2002 Phase I trial of 1 alpha-hydroxyvitamin D (2) in patients with hormone refractory prostate cancer Clin Cancer Res 8 2820 2827
5. G Liu G Wilding MJ Staab 2003 Phase II study of 1 alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer Clin Cancer Res 9 4077 4083
6. MA Carducci RJ Padley JV Breul 2003 Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial J Clin Oncol 21 679 689
7. JB Nelson AA Nabulsi NJ Vogelzang 2003 Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan J Urol 169 1143 1149
8. S Fujiyama H Matsubara Y Nozawa 2001 Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation Circ Res 88 22 29
9. H Uemura H Ishiguro N Nakaigawa 2003 Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor Mol Cancer Ther 2 1139 1147
10. GJ Bubley M Carducci W Dahut 1999 Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 3461 3467
11. H Ishiguro N Nakaigawa Y Miyoshi 2005 Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin, are overexpressed and associated with prostate cancer progression Prostate 64 92 100
12. H Hasumi H Ishiguro M Nakamura 2005 Neuroserpin (pi-12) is up-regulated in high-grade prostate cancer and is associated with survival Int J Cancer 115 911 916
13. AW Hahn U Jonas FR Buhler 1994 Activation of human peripheral monocytes by angiotensin II FEBS Lett 347 178 180
14. EK Rice GH Tesch Z Cao 2003 Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II Kidney Int 63 1265 1275
15. H Sato A Watanabe T Tanaka 2003 Regulation of the human tumor necrosis factor-alpha promoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and transcriptional factors J Mol Cell Cardiol 35 1197 1205
16. B Amann R Tinzmann B Angelkort 2003 ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1 Diabetes Care 26 2421 2425
17. DW Moskowitz FE Johnson 2004 The central role of angiotensin-converting enzyme in vertebrate pathophysiology Curr Top Med Chem 4 1433 1454
18. AF Lever DJ Hole CR Gillis 1998 Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 179 184
19. ME Ullian LG Walsh TA Morinelli 1996 Potentiation of angiotensin II action by corticosteroids in vascular tissue Cardiovasc Res 32 266 273
20. DF Guo S Uno T Inagami 1995 Steroid hormones upregulate rat angiotensin II type 1A receptor gene: role of glucocorticoid responsive elements in rat angiotensin II type 1A promoter J Steroid Biochem Mol Biol 53 69 73
21. M Sano K Fukuda T Sato 2001 ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts Circ Res 89 661 669
22. CJ Logothetis KK Wu LD Finn 2001 Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer Clin Cancer Res 7 1198 1203
23. K Egami T Murohara T Shimada 2003 Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth J Clin Invest 112 67 75
24. D Ingber T Fujita S Kishimoto 1990 Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature 348 555 557
25. M Yamaoka T Yamamoto T Masaki 1993 Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl- carbamoyl) fumagillol (TNP-470; AGM-1470) Cancer Res 53 4262 4267
26. MC Hall P Troncoso A Pollack 1994 Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy Urology 44 869 875
27. WD Figg W Dahut P Duray 2001 A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 1888 1893